498P Efficacy and safety of triptorelin pamoate 22.5 mg 6-month formulation in Chinese patients with locally advanced or metastatic prostate cancer: A multicentre, single-arm phase IIIb study
498P Efficacy and safety of triptorelin pamoate 22.5 mg 6-month formulation in Chinese patients with locally advanced or metastatic prostate cancer: A multicentre, single-arm phase IIIb study is a paper indexed in ScholarIQ from OpenAlex.
How many citations does 498P Efficacy and safety of triptorelin pamoate 22.5 mg 6-month formulation in Chinese patients with locally advanced or metastatic prostate cancer: A multicentre, single-arm phase IIIb study have?
498P Efficacy and safety of triptorelin pamoate 22.5 mg 6-month formulation in Chinese patients with locally advanced or metastatic prostate cancer: A multicentre, single-arm phase IIIb study has 0 citations in the OpenAlex counts ScholarIQ stores.
When was 498P Efficacy and safety of triptorelin pamoate 22.5 mg 6-month formulation in Chinese patients with locally advanced or metastatic prostate cancer: A multicentre, single-arm phase IIIb study published?
498P Efficacy and safety of triptorelin pamoate 22.5 mg 6-month formulation in Chinese patients with locally advanced or metastatic prostate cancer: A multicentre, single-arm phase IIIb study has 2025 year in the ScholarIQ index.
What is the open-access status of 498P Efficacy and safety of triptorelin pamoate 22.5 mg 6-month formulation in Chinese patients with locally advanced or metastatic prostate cancer: A multicentre, single-arm phase IIIb study?
498P Efficacy and safety of triptorelin pamoate 22.5 mg 6-month formulation in Chinese patients with locally advanced or metastatic prostate cancer: A multicentre, single-arm phase IIIb study has closed oa status in the ScholarIQ index.
What is the DOI of 498P Efficacy and safety of triptorelin pamoate 22.5 mg 6-month formulation in Chinese patients with locally advanced or metastatic prostate cancer: A multicentre, single-arm phase IIIb study?
The DOI for 498P Efficacy and safety of triptorelin pamoate 22.5 mg 6-month formulation in Chinese patients with locally advanced or metastatic prostate cancer: A multicentre, single-arm phase IIIb study is on the source record.
What is the OpenAlex record for 498P Efficacy and safety of triptorelin pamoate 22.5 mg 6-month formulation in Chinese patients with locally advanced or metastatic prostate cancer: A multicentre, single-arm phase IIIb study?
The OpenAlex for 498P Efficacy and safety of triptorelin pamoate 22.5 mg 6-month formulation in Chinese patients with locally advanced or metastatic prostate cancer: A multicentre, single-arm phase IIIb study is on the source record.